8 completed, 4 unknown, 1 recruiting, 1 terminated. 14 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 8, Unknown 4, Recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 2, Unknown 2, Recruiting 1 |
Follow Mastocytosis: new trials by email Literature Review of Mastocytosis trials Research Report on Mastocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Elenestinib, Placebo - Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | Phase 2 / Phase 3 | Recruiting | Blueprint Medicines Corporation | 534 | 2021-11-30 | 2026-10-07 |
| Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients Hydroxychloroquine - Mastocytosis | Phase 2 / Phase 3 | Unknown | University Hospital, Toulouse | 30 | 2021-10-01 | 2021-10-20 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Unknown | AB Science | 140 | 2020-07-01 | 2023-05-06 |
| Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis Denosumab, Placebo - Osteoporosis, Systemic Mastocytosis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 24 | 2018-03-05 | 2026-03-31 |
| Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis Cladribine and pegylated interpheron alpha-2a - Systemic Mastocytosis | Phase 2 / Phase 3 | Unknown | Hospital Virgen de la Salud | 10 | 2012-05-01 | 2016-08-29 |
| The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients injections - Mastocytosis | Phase 2 / Phase 3 | Completed | University of Zurich | 17 | 2011-09-01 | 2016-01-18 |
| Study on Mastocytosis for Rupatadine Treatment Rupatadin - Mastocytosis | Phase 2 / Phase 3 | Completed | Marcus Maurer | 30 | 2010-09-01 | 2016-11-03 |
| Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer cyproheptadine hydrochloride, placebo - Cancer | Phase 3 | Terminated | University of South Florida | 22 | 2010-06-01 | 2015-07-02 |
| Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain ketamine hydrochloride, pharmacogenomic studies, questionnaire administration - Cancer | Phase 3 | Unknown | University of Glasgow | 214 | 2009-04-01 | 2011-05-13 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Completed | AB Science | 135 | 2008-12-01 | 2019-12-03 |
| American Ginseng in Treating Patients With Fatigue Caused by Cancer American ginseng, placebo - Chronic Myeloproliferative Disorders, Fatigue | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 364 | 2008-10-01 | 2017-02-09 |
| Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial educational intervention - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 3 | Completed | Case Comprehensive Cancer Center | 583 | 2008-04-01 | 2020-07-27 |
| Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose - Anemia, Leukemia | Phase 3 | Completed | Mayo Clinic | 502 | 2006-01-01 | 2011-05-17 |
| Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain educational intervention, Titrated pain management, questionnaire administration - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 3 | Completed | Vanderbilt-Ingram Cancer Center | 98 | 2005-05-01 | 2012-09-06 |
Lymphoma, Large-Cell, Anaplastic (6) · Burkitt Lymphoma (5) · Hodgkin Disease (5) · Immunoblastic Lymphadenopathy (5) · Immunoglobulin Light-chain Amyloidosis (5) · Leukemia, Biphenotypic, Acute (5) · Leukemia, Hairy Cell (5) · Leukemia, Large Granular Lymphocytic (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Leukemia, Mast-Cell (5) · Leukemia, Prolymphocytic (5) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Extranodal NK-T-Cell (5) · Lymphoma, Follicular (5)
Immune System Diseases (14) · Neoplasms by Histologic Type (14) · Mast Cell Activation Disorders (13) · Neoplasms (12) · Neoplasms, Connective Tissue (9) · Neoplasms, Connective and Soft Tissue (9) · Metabolic Diseases (8) · Nutritional and Metabolic Diseases (8) · Pathological Conditions, Signs and Symptoms (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Hemic and Lymphatic Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma, T-Cell (6)
Early Intervention, Educational (2) · masitinib (2) · Asian ginseng (1) · Cladribine (1) · Cyproheptadine (1) · Darbepoetin alfa (1) · Denosumab (1) · Hydroxychloroquine (1) · Injections (1) · Ketamine (1) · Pharmacogenomic Testing (1) · Sucrose (1) · ferric gluconate (1) · ferrous sulfate (1)
AB Science (2) · Alliance for Clinical Trials in Oncology (1) · Assistance Publique - Hôpitaux de Paris (1) · Blueprint Medicines Corporation (1) · Case Comprehensive Cancer Center (1) · Hospital Virgen de la Salud (1) · Marcus Maurer (1) · Mayo Clinic (1) · University Hospital, Toulouse (1) · University of Glasgow (1) · University of South Florida (1) · University of Zurich (1) · Vanderbilt-Ingram Cancer Center (1)
United States (7) · France (5) · Germany (3) · United Kingdom (3) · Netherlands (2) · Poland (2) · Romania (2) · Spain (2) · Switzerland (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1)
Barry J.A. Laird, MD (1) · Charles L. Loprinzi, MD (1) · Cristina Bulai Livideanu, MD, MSc (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Jeffrey P. Krischer, PhD (1) · Luis Escribano, MD, PhD (1) · Maella Severino-Freire, MD (1) · Marcus Maurer, MD (1) · Marie T. Fallon (1) · Nancy Wells, DNSc, RN (1) · Neal J. Meropol, MD (1) · Olivier Hermine, MD (1) · Olivier Lortholary, MD, PhD (1)
PMID 26700120, PMID 26700123, PMID 28069279, PMID 36048877
2016 (2), P30CA015083 (1), P30CA068485 (1), R01CA127655 (1), U10CA081920 (1)